Supplemental material
Leukemia & Lymphoma
Volume 65, 2024 - Issue 1
Original Articles
The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience
Magdalena Olszewska-Szopaa Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
https://orcid.org/0000-0002-5828-0872View further author information
https://orcid.org/0000-0002-5828-0872View further author information, Agnieszka Ożańskaa Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, PolandCorrespondence[email protected]
https://orcid.org/0000-0002-2924-3837View further author information
https://orcid.org/0000-0002-2924-3837View further author information, Tomasz Ożańskib Wroclaw University of Science and Technology, Wroclaw, Polandhttps://orcid.org/0000-0003-3331-6637View further author information
https://orcid.org/0000-0003-3331-6637View further author information, Justyna Rybkaa Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Polandhttps://orcid.org/0000-0001-7965-3589View further author information
https://orcid.org/0000-0001-7965-3589View further author information & Tomasz Wróbela Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Polandhttps://orcid.org/0000-0002-6612-3535View further author information
https://orcid.org/0000-0002-6612-3535View further author information